Preface to the 11th Edition Eight years after the publication of the 10th edition in 2007, the 11th edition of the Japanese Classification of Esophageal Cancer has now been published. During this period, supplements to the 10th edition involving the revision of ''disease typing'' and terminology were published in 2008; in addition, following the adoption of criteria for the diagnosis of lesions located at the gastroesophageal junction that was made in cooperation with the Japanese Gastric Cancer Association, a 7-page leaflet was attached to this Classification in September 2013. The present revision was aimed at ensuring consistency with other general rules for surgical and pathological studies on cancer as far as possible, reflecting the latest advances in the diagnosis and treatment of esophageal cancer in Japan and providing a set of rules that are easier to use and that facilitate improvements in treatment outcomes. During this revision, we attempted to secure consistency with the UICC's TNM classification as far as possible. However, this attempt was skipped for the N classification, since the current edition (7th) of the TNM classification does not reflect the nationwide registry data of the Japan Esophageal Society and because the rules for studies on supraclavicular lymph nodes are completely different between our classification and the N classification. This is a significant issue that will need to be addressed in the next revision.
Using nationwide registry data, the effects of regional lymph node excision were reviewed from the viewpoints of lymph node metastasis and the survival rate. As a result, the lymph node groupings were modified (T4 was subdivided into two subtypes, similar to the TNM classification). Following recent advances and the spread of endoscopic treatment, findings from endoscopic treatment have now been incorporated into the description methods, and the exclusion of cancer from intraepithelial neoplasms has been clarified. This revised edition has been prepared as a result of numerous discussions among committee members. Although there are still some questions to be discussed, we wish to take this opportunity to thank the considerable efforts made by the individual committee members.
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General principles of this edition 1. Following the spread of endoscopic treatment, findings from endoscopic treatment (e) have been added to the methods used to describe findings.
2. The criteria for the diagnosis of lesions located at the gastroesophageal junction, which have been jointly adopted by the Japanese Gastric Cancer Association, have been added to the main text.
3. Regarding the depth of tumor invasion, the subgroup T1b-has been added to the subgroup T1b, similar to that for T1a, and the subgroup T4 has been further subdivided into T4a and T4b so as to be consistent with the UICC's TNM classification.
4. Regarding lymph nodes, No. 112ao has been divided into the esophageal side and the dorsal side. Furthermore, to secure consistency with the general rules for surgical and pathological studies on gastric cancer, No. 3 has been divided into No. 3a and No. 3b.
5. Regarding lymph node grouping, modifications have been made to Ut (Group 3 only), Mt/Lt (Groups 1, 2, 3), and Ae (Groups 2, 3). In accordance with the revision of the criteria for the diagnosis of lesions located at the gastroesophageal junction, the same lymph node classification as that used for Ae will now be applied to cancer of the gastroesophageal junction.
6. Regarding the stage of cancer, T1aN1 is now classified as Stage II, as is the case with T1bN1. T4a up to N3 is now classified as Stage III. T4b, beginning with N0, is now classified as Stage IVa.
7. Regarding the extent of residual cancer, classification into R1 based on macroscopic findings is now avoided, consistent with the general rules for surgical and pathological studies on colorectal cancer.
8. Regarding histopathological findings, it has now been made clear that carcinoma in situ is not to be included among neoplasms within the squamous epithelium. The extent of differentiation of both squamous cell carcinoma and adenocarcinoma is now described as ''well differentiated'' or a similar expression, omitting any description of type. Endocrine cell neoplasm is now called neuroendocrine tumor, consistent with the WHO classification. Also, concerning extralymph node metastasis, the expression ''tumor nodule'' has been adopted, consistent with the general rules for surgical and pathological studies on colorectal cancer. Vascular invasion in specimens collected during endoscopic treatment is now rated as (-) or (?), consistent with the method used for gastric cancer.
9. The TNM classification adopted for the revised classification has been switched to the Japanese translation of the TNM classification, 7th edition.
10. Regarding the number of lymph node metastases, the conventional rule for the correction of grouping according to the number of metastases was too complex and was not used frequently. This rule has been deleted from the revised edition.
11. The endoscope pictures have been replaced with clearer ones.
12. Regarding the extents and borders of the lymph nodes, not only schematic figures, but also actual CT images have been provided to simplify understanding, accompanied by the presentation of features that will also be useful for radiotherapy. To promote the international use of the Guidelines and the Classification, the Society is publishing this handbook in English entitled ''The Japanese Classification of Esophageal Cancer''.
Abbreviations

Object
The term esophageal cancer in the Japanese Classification refers to cancer originating in the esophagus, and cancer metastatic to the esophagus is excluded. All primary malignant tumors in the esophagus should be described according to the Japanese Classification.
Methods of descriptions
Principles of descriptions and abbreviations
Findings are recorded using upper-case letters T (depth of tumor invasion), N (lymph node metastasis) and M (distant organ metastasis). The extent of each finding is expressed by Arabic numerals following each uppercase letter. ''X'' is used in unknown cases. Five categories of findings, namely Clinical, Endoscopic treatment, Surgical, Pathological, and Final findings, are identified using the lower case ''c'', ''e'', ''s'', ''p'', and ''f'', respectively, before each upper-case letter. The ''f'' of Final findings can be omitted (Tables 1-1, 1-2) . Checklists for descriptions of the Japanese Classification of Esophageal Cancer are shown in the following tables (Tables 1-3 , 1-4).
The order of clinicopathological description is: Tumor location (in addition to describing the distance from the incisor), circumferential extent, tumor length, macroscopic tumor type, histological type (when identified), depth of tumor invasion, lymph node metastasis, distant organ metastasis and stage. As the tumor responded to chemoradiotherapy, surgery was performed; CRT-sT3, sN2, sM0, sStage III Although the tumor completely responded to chemoradiotherapy on pathological findings, metastasis to Group 3 lymph nodes was observed; CRT-pT0 (T3), pN3, sM0, pStage III 
Findings modified by treatment methods other than surgery are abbreviated as follows: RT radiotherapy, CT chemotherapy, CRT chemoradiotherapy, EMR endoscopic mucosal resection, ESD endoscopic submucosal dissection, laser laser therapy, PDT photodynamic therapy Maximum length (mm) and orthogonally oriented maximum width (mm), center of circumferential extent, and circumferential ratio of the tumor to the entire esophagus should be described. In addition, the methods used for diagnosis, such as barium X-ray, endoscopy and EUS, should be recorded.
Tumor location
Anatomical definition of the esophagus
The esophagus is defined anatomically from the esophageal orifice to the esophagogastric junction. The esophageal orifice is at the lower margin of the cricoid cartilage. The identification of the esophagogastric junction (EGJ) will be described later.
Anatomical regions (subsites) of the esophagus
The esophagus lies between the hypopharynx and stomach, and can be anatomically divided into the following portions; cervical esophagus (Ce), thoracic esophagus (Te) and abdominal esophagus (Ae). The zone of the esophagogastric junction is divided into the esophageal side (E) and gastric side (G) (Fig. 1-1 ).
Note
Cervical esophagus (Ce): This extends from the esophageal orifice to the sternal notch. Thoracic esophagus (Te): From the sternal notch to the superior margin of the esophageal hiatus. Upper thoracic esophagus (Ut): From the sternal notch to the tracheal bifurcation.
Middle thoracic esophagus (Mt): The proximal half of the two equal portions between the tracheal bifurcation and the esophagogastric junction.
Lower thoracic esophagus (Lt): The thoracic part of the distal half of the two equal portions between the tracheal bifurcation and the esophagogastric junction. Abdominal esophagus (Ae): The abdominal part of the distal half of the two equal portions between the tracheal bifurcation and the esophagogastric junction (from the Note: The zone of the esophagogastric junction is defined as the region between 2 cm in esophagus and 2 cm in the stomach from the esophagogastric junction. The abdominal esophagus is included in this zone.
Principles of description of tumor location
Describe the tumor location identified by examinations according to the following order of priority: barium X-ray, CT, and endoscopic measurements. Include the distance from the incisor in addition to the tumor location. When the tumor location is uncertain because examinations other than endoscopy have yet to be performed, describe only the distance from the incisor. When the tumor extends continuously in more than one portion of the esophagus, the main tumor location is that with the deepest tumor invasion. If it is difficult to determine the site of deepest tumor invasion, the portion at the central point of the tumor can be recorded as the main tumor location. In the case of multiple primary lesions, the locations of the lesions are described in the order of depth of tumor invasion. The deepest lesion is described first. If it is difficult to determine the order of the depth, the description order depends on the size of the area occupied by the lesion. The largest lesion is described first. e.g.: MtLt, LtAeG. 2.1.3.2. Macroscopic classification ( Fig. 1-2 Note 1: The macroscopic tumor type before chemotherapy and/or radiotherapy is described. Previous treatment is indicated. Cases with minor changes following treatment and which fit the macroscopic tumor type(s) are classified as type 1-4 and cases of major changes are designated as unclassifiable type. Note 2: Any former treatment(s) is mentioned before the macroscopic tumor type. e.g.: CT-3, CRT-5b, EMR-0-IIc Note 1: Combined type: When multiple macroscopic tumor types are mixed in one lesion, it is called a combined type. The wider type is described first and types are connected with ?. Double quotation marks ('''') are placed around the macroscopic tumor type that has the deepest tumor invasion. In this case, the main macroscopic tumor type is the deepest one. However, when an advanced type is mixed with a superficial type, the advanced type is described first and double quotation marks are unnecessary. e.g.: 0-IIc?''0-Is'', 3?0-IIc. Note 2: Superficial spreading type: superficial type 0-II in which the maximal length of the tumor extends 5 cm or more longitudinally. It may be noted additionally in the macroscopic tumor type.
[Reference] Japanese Society for Esophageal Diseases. Guidelines for the Clinical and Pathologic Studies on Carcinoma of the Esophagus (in Japanese). 8th ed. Kanehara Shuppan, Tokyo, 1992; 34.
Depth of tumor invasion (T)
TX Depth of tumor invasion cannot be assessed T0 No evidence of primary tumor T1a Tumor invades mucosa Note 1 (Fig 1-3 [Reference]
Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma. 14th ed. Kanehara Shuppan, Tokyo, 2010. Nodes other than N1 through N3 are expressed as N4 a Limited to the area which can be dissected from the cervical incision Note: Extralymph node metastasis (tumor nodule) is included within N. 
Fig. 1-4 Station numbers of regional lymph nodes
Distant organ metastasis (M)
MX
Multiple primary cancers
Multiple primary cancers of the esophagus: The term ''multiple primary cancers of the esophagus'' is used to refer to the presence of two or more primary esophageal cancers. 
Multi-organ primary cancers including the esophagus:
The term ''multi-organ primary cancers including the esophagus'' is used to refer to the presence of one or more primary malignant diseases other than esophageal cancer in a patient with primary esophageal cancer. Multiple primary cancers including the esophagus: The term ''multiple primary cancers including the esophagus'' indicates the concept combining both ''multiple primary cancers of the esophagus'' and ''multi-organ primary cancers including the esophagus''.
Note 1: In cases with multi-organ primary cancers including the esophagus, organs other than the esophagus should be specified in parentheses. Note 2: Whether the multiplicity is synchronous or metachronous should be recorded. e.g.: Multi-organ primary cancers: stomach (synchronous).
Surgical aspects
Handling of the resected specimen
The resected esophagus should be cut and opened along the longitudinal line on the side opposite to the lesion. The opened esophagus should be gently stretched longitudinally and fixed so that the length of the specimen becomes similar to its size in vivo. The specimen should be treated with iodine solution after fixation in order to accurately describe the macroscopic findings. This is particularly important in superficial carcinoma. Photographic recording is recommended for both fresh and fixed specimens.
Description of surgical findings and macroscopic findings of primary tumor
Operative findings should be identified in the record putting ''s'' in front of each factor. e.g.: sT2, sStageII.
3.2.1. Tumor size (Fig. 1-13) The greatest longitudinal dimension in millimeters and the greatest transverse (at 90°to the longitudinal tumor axis) dimension in millimeters: a 9 b (mm) N0  N1  N2  N3  N4  M1   T0, T1a  0  II  II  III  IVa  IVb   T1b  I  II  II  III  IVa  IVb   T2  II  II  III  III  IVa  IVb   T3  II  III  III  III  IVa  IVb   T4a  III  III  III  III  IVa  IVb   T4b  IVa  IVa  IVa  IVa  IVa  IVb T4a pleura, pericardium, diaphragm, lung, thoracic duct, azygos vein, nerve T4b aorta (large vessel), trachea, bronchus, pulmonary vein, pulmonary artery, vertebra 3.2.2. Distance from surgical margin to the tumor ( Fig. 1-13) Proximal (oral) margin (PM) (mm) Distal (anal) margin (DM) (mm)
Macroscopic tumor type
The macroscopic appearance of tumors before and after fixation can be different. Under such circumstances, the macroscopic tumor type should be described according to prefixation observations, and the pathological tumor type should be described based on the post-fixation findings. Pathological tumor types can be classified referring to the cross-sectional observation. Macroscopic tumor types should be determined regardless of microscopic depth of tumor invasion.
Note: The presence of preoperative chemotherapy and radiotherapy should be recorded with the macroscopic tumor type. Note: The radial margin is the surgical margin in the radial direction, i.e., the outer surface of the surgical dissection plane.
Intramural metastasis and multiple cancers in the esophagus
IM: Intramural metastasis
Metastatic lesions in the esophageal, pharyngeal, or gastric wall macroscopically (clearly) separate from the primary tumor should be recorded as IM, and the number of such lesions should be described.
IMX Intramural metastasis cannot be assessed IM0 No intramural metastasis IM1 Intramural metastasis
Note: IM in the gastric wall should be recorded as ''IM1-St''. It is classified as organ metastasis (M1).
Multiple cancers of the esophagus
Multiple cancers are two or more primary cancer lesions separate from each other. Multiple cancers and IM should be clearly differentiated in the description.
Lymph nodes
Preparation of resected lymph nodes for pathological examination
Surgically dissected lymph nodes are classified according to the definition of regional lymph nodes, given individual names or numbers and sent to pathologists. The lymph nodes dissected en bloc with the esophagus should be isolated from the specimen before fixation.
Grading of lymph node metastasis (N)
The surgical diagnosis of the grading of lymph node metastasis (sN) should be made comprehensively with intraoperative findings of macroscopic observation, imaging examinations, immediate pathological diagnosis with frozen section, and macroscopic findings obtained during postoperative preparation. Surgical findings of distant organ metastasis (sM) should be determined through comprehensive consideration of operative macroscopic findings, intraoperative imaging examinations such as intraoperative ultrasound examination, macroscopic observation of resected specimen, and intraoperative immediate pathological diagnosis with frozen section. Whether the distant organ metastasis was resected or not should be recorded.
Lymph node dissection (D)
3
Residual tumor (R)
Note 1 (Fig. 1-14) RX Presence of residual tumor cannot be assessed. 3.7. Curativity (Cur) ( Table 1-8) Cur A Complete removal of the tumor is strongly believed. sStage 0-III, and sR0, and sD [ sN ( Fig. 1-14) .
Cur B Neither Cur A nor Cur C R1. sStage IVa, sStage IVb or sD^sN, but R0 was achieved with resection of a T4b tumor or complete removal of metastatic tumor (M1) or lymph nodes.
Cur C Residual tumor. R2, i.e., M1 evident residual tumor in distant organ(s) (M1), lymph nodes, or surgical margin(s) (PM1, DM1, RM1).
Pathological findings
4.1. Handling of the surgically resected specimens ( Fig. 1-15) Before cutting the resected esophagus, the formalin-fixed specimen should be treated with iodine solution to confirm the unstained area. Rinsing the sample with tap water for at least 1 h can result in a good staining condition. To increase the contrast between stained and unstained areas, the sample should be treated with a relatively low concentration (0.1-0.5%) of iodine solution for a long time.
The resected specimen should be cut parallel along the long axis of the esophagus. Whole step sections are made in superficial type cancer. One representative section of an advanced tumor at the site of deepest invasion, parallel or perpendicular to the esophagus should be blocked and used for microscopic examination. Schemas or photographs of the sites of cut sections should be preserved. 
Description of pathological findings
The p (pathology) mark is prefixed to the pathological findings except for vascular invasion as follows. e.g.: p0-Is, pType 2, pT2, pStagedII.
carcinoma (pT1a-EP carcinoma) or squamous cell carcinoma in situ can be diagnosed when cellular and structural atypia are sufficient to suggest malignancy. The 10th edition mentioned that low-grade intraepithelial neoplasia might contain basal-type squamous cell carcinoma. When such lesions are distributed in the lower half of the epithelium and are sufficiently atypical to suggest malignancy, the lesion can be diagnosed as squamous cell carcinoma according to the classification of the 11th edition. Note 4: Most ''squamous intraepithelial neoplasias'' according to the definition of the 11th edition are endoscopically or macroscopically recognized as a ''small unstained or tan-stained area''. The lesion may be solitary or multiple. Note 5: According to the definition of the 11th edition, intraepithelial neoplastic lesion without atypia sufficient to suggest malignancy is termed as squamous intraepithelial neoplasia. Thus, intraepithelial neoplasia does not include squamous cell carcinoma in situ. Please be careful to note the differences in the definitions of intraepithelial neoplasia between the 10th and 11th editions. A two-tier subclassification of intraepithelial neoplasia (low grade and high grade) is not used in the 11th edition. In making a diagnosis of intraepithelial neoplasia based on a biopsy specimen, the inclusion of one of the following comments is recommended: ''follow-up is needed'', ''re-biopsy after a short time period should be recommended'', or ''immediate rebiopsy is strongly recommended because of suspicious carcinoma''. Note 6: When the determination of a biopsy specimen as ''neoplastic'' or ''reactive'' is difficult, the specimen should not be diagnosed as ''intraepithelial neoplasia'', but rather as ''atypical epithelium'' or ''atypical epithelium, indefinite for neoplasia''. For clinicians, the inclusion of instructions such as the need for a re-biopsy is recommended. Note 7: Squamous cell carcinoma, which is limited to within the epithelial layer without invasion, is different from squamous intraepithelial neoplasia. Squamous cell carcinoma in situ is equal to squamous cell carcinoma with a depth of pT1a-EP. Note 8: Neuroendocrine tumor and neuroendocrine carcinoma are formally classified as carcinoid tumor and endocrine cell carcinoma, respectively. These terms have been adopted according to the WHO classification. In Japan, however, ''endocrine cell carcinoma'' is considered to be the correct term, since endocrine cells in the gastrointestinal tract originate from gastrointestinal stem cells.
Depth of tumor invasion (pT)
Note 1-7
Note 1: Intraductal spreading of cancer is categorized as pT1a-EP, and if the tumor invades beyond the duct of the esophageal gland, the depth of tumor invasion is defined as the layer presenting extraductal invasion of cancer. Note 2: The vertical depth of submucosal invasion is measured from the muscularis mucosae, and the depth is recorded in parentheses. e.g.: pT1b-SM2 (400 lm). Note 3: The depth of tumor invasion is defined histologically as the point of deepest direct invasion by the primary tumor. Vascular invasion within the confines of the primary tumor should be regarded as the depth of direct tumor invasion. However, when vascular invasion is found outside the confines of the primary tumor, the depth of such invasion should be specified in parentheses after the depth of direct invasion. For example, when a primary tumor has invaded into the submucosa (pT1b) but lymphatic invasion is found in the muscularis propria outside the main tumor, this is designated as pT1b (ly-T2). Note 4: Cancer that has macroscopically invaded adjacent organ(s) (sT4) and histologically diagnosed malignant tissue recognized on the surgical radial margin (pRM1) are categorized as pT4. Note 5: Direct invasion of tumor from lymph node metastasis to the adjacent organ(s) is categorized as pT4. e.g.: Direct invasion from No.108 lymph node metastasis to the lung: pN1 (108-lung) T4a Note 6: In determining the depth of invasion of an advanced cancer after preoperative treatment, both the depth of invasion by residual tumor and the estimated depth of tumor invasion prior to treatment should be considered. The type of adjuvant therapy (RT-, CT-, CRT-, EMR-), depth of invasion by the residual tumor, and estimated depth of tumor invasion prior to treatment should be specified in the given order, with the last item in parentheses. e.g.: RT-pT1b (T4). Note 7: If no residual tumor is found in an entire specimen after preoperative treatment, the designation should be pT0, and its stage is recognized as the same as T1a. e.g.: CRT-pT0 (T3), N0, M0, CRT-pStage 0.
Infiltrative growth pattern (INF)
The growth and infiltrative pattern of tumor can be classified into one of the following three types, with regard to the predominant pattern observed at tumor margins. eHMX Whether residual tumor is present on the horizontal margin cannot be assessed. eHM0 Non-cancerous squamous epithelium and lamina propria mucosae have been confirmed on all horizontal resection margins. eHM1 The tumor is exposed on one of its horizontal resection margins.
Vertical margin (eVM)
eVMX Whether residual tumor is present on the vertical margin cannot be assessed. eVM0 The tumor is not exposed on any of its vertical margins. eVM1 The tumor is exposed on one of its vertical margins. Presence of an iodine-unstained area on the margin of the resected specimen. eR2 (incomplete resection)
Presence of residual tumor.
Note 1: The clinical assessment of the residual tumor, referring to the iodine staining of the resected specimen, should be performed immediately after the endoscopic resection. In cases with a piecemeal resection, iodine staining of the ulcer margin after resection should be referenced.
Note 2: This assessment method should be applied to squamous cell carcinoma. (Fig. 1-17) Before cutting, formalin-fixed specimen should be stained with iodine solution to confirm unstained area.
Preparation for pathological examination
Note Cutting lines are decided as crossing lines at right angles to the tangent line at the resection margin closest to the tumor, and a whole resected specimen is cut in slice each 2-3 mm thick.
Note: Rinsing the sample with tap water for at least 30 min can result in a good staining condition. To make a clearer contrast between stained and unstained areas, the sample should be treated with relatively low concentration (0.1-0.5%) of iodine solution for a little bit longer time.
Description of pathological findings
The pathological diagnosis of an endoscopically resected specimen is summarized by the histological type, depth of tumor invasion, assessment of resection margin (horizontal and vertical), and vascular invasion.
Pathological diagnosis
The diagnosis is based on the histological classification (4.2.1). Although most esophageal tumors are squamous cell carcinoma, the evaluation of histological differentiation is omitted for intraepithelial carcinoma.
Depth of tumor invasion (pT)
A mucosal cancer is categorized in three depths of pT1a-EP, pT1a-LPM and pT1a-MM. In a submucosal cancer, the Fig. 1-17 How to cut endoscopically resected specimens distance from the lamina muscularis mucosae is described because the entire submucosal layer cannot be examined in an endoscopically resected specimen. A submucosal cancer is sub-classified as pT1b-SM1 (submucosal tumor invasion limited to within 200 lm) and pT1b-SM2 (invasion to more than 200 lm). e.g.: pT1b-SM2, 300 lm.
pR0 No cancer tissue is pathologically present at any margin of the resected specimen. pR1 Cancer tissue is pathologically present at the margin of the resected specimen. pR2 A cancer lesion is present.
Note 1: For a piecemeal resection, the presence of residual tumor is evaluated after rebuilding the specimen. Note 2: When multiple lesions are resected, each lesion is evaluated individually.
5.6. Curativity (pCur) When endoscopic resection (EMR: endoscopic mucosal resection, or ESD: endoscopic submucosal dissection) is performed for superficial esophageal cancer that does not exhibit clinical metastasis, a comprehensive evaluation can be established, based on the pathological findings of depth of invasion, residual tumor, and vascular invasion (Table 1- The EGJ should be defined systematically in accordance with the criteria listed below. Among these criteria, endoscopic findings should be given priority over findings obtained using other diagnostic modalities.
Endoscopic findings
Lower margin of palisading small vessels If the palisading small vessels are unclear, the oral margin of the longitudinal folds of the greater curvature of the stomach is defined as the EGJ.
Upper gastrointestinal series (UGI)
Narrowest locus of the lower esophagus In the presence of a sliding hiatal hernia, the upper end of the longitudinal folds is defined as the EGJ. In the presence of Barrett esophagus, the upper end of the longitudinal folds is defined as the EGJ.
Pathological study
Macroscopic definition: The EGJ should be defined macroscopically as the point at which the luminal caliber changes in the area where the tubular esophagus is connected to the vestibule lumen of the stomach.
Microscopic definition: For a mucosal layer with intact structures, the EGJ should be defined as follows:
1. Non-Barrett esophagus: The EGJ is defined as the squamocolumnar junction. 2. Barrett esophagus: Histological structures such as proper esophageal glands and their ducts, a double-layer muscularis mucosae, or palisading small vessels should be included in the microscopic definition of the EGJ.
For a non-intact mucosal layer, the EGJ should be defined based on the macroscopic findings of the surgical specimen, and the EGJ should be presumed based on the presence of histological structures associated with the esophagus or stomach.
Barrett mucosa
Columnar epithelium continuous from the stomach with or without intestinal metaplasia
Barrett esophagus
An esophagus containing Barrett mucosa should be designated as Barrett esophagus.
Note 1
At least one of the following conditions must be satisfied.
1. Presence of esophageal gland ducts in the mucosal layer or proper esophageal glands in the submucosal layer within the area of columnar epithelium. 2. Presence of squamous islands in the columnar epithelium. T1a-SMM Tumor has invaded the superficial muscularis mucosae (SMM). T1a-LPM Tumor has invaded the lamina propria mucosae. T1a-DMM Tumor has invaded the deep muscularis mucosae (DMM).
T1b Tumor has invaded the submucosa (SM).
SM1 Tumor has invaded the upper third of the submucosa. Planned surgery: planned surgery after neoadjuvant chemotherapy, radiotherapy, or both. Salvage surgery: surgery for cases with residual tumor or cases with recurrent tumor after definitive chemoradiotherapy with more than 50 Gy radiation. The surgical methods, such as esophagectomy, lymphadenectomy, endoscopic resection, and so on, should be described. This is the period during which the esophagus is preserved in patients with esophageal cancer who underwent nonesophagectomy treatment such as endoscopic mucosal resection, endoscopic submucosal dissection, chemotherapy and/or radiotherapy. The rate of those patients per all patients who underwent treatment for esophageal cancer is described.
[Reference] Time until death regardless of cause from the initial date. In observation studies, the day starting treatment, or the day confirming diagnosis is used as the initial date. In clinical trials, the ''registration date'' (the allocation day in the case of a randomized controlled trial) is used.
Median survival time (MST)
Period from the initial date to the first date of the survival rate being less than 50% in the survival curve calculated by the Kaplan-Meier method. The initial date is the same as described in 8.9.2.
Survival rate
The rate of survivors at a given time 8.9.5. Progression-free survival (PFS), time to progression (TTP)
It is the shortest period among periods from the initial date to progression or recurrence, or death. Death from any cause is regarded as an event, in PFS. Death is only regarded as an event if it is caused by esophageal cancer, in TTP.
8.9.6. Relapse-free survival, recurrence-free survival (RFS) This is the period between the initial date to recurrence or death.
The day when the disease-free state was achieved such as an operation day, is used as the initial date.
Disease-free survival (DFS)
It is the shortest period among the periods from the initial date to a recurrence, death, or diagnosis of a second primary cancer. The day when the disease-free state such as an operation day was achieved, is used as the initial date.
Time to treatment failure (TTF)
This is the shortest period among the periods from the initial date to treatment cessation, progression, and death.
Response duration
Period from the first day when the disease was assessed as CR or PR until progression.
Complete response duration
Period from the first day when the disease was assessed as CR until recurrence. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://crea tivecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
